TY  - GEN
AU  - Diago-Sempere, Elena
AU  - Bueno, José Luis
AU  - Sancho-López, Aránzazu
AU  - Múñez Rubio, Elena
AU  - Torres, Ferrán
AU  - Malo de Molina, Rosa
AU  - Fernández-Cruz, Ana
AU  - Salcedo de Diego, Isabel
AU  - Velasco-Iglesias, Ana
AU  - Payares-Herrera, Concepción
AU  - Casas Flecha, Inmaculada
AU  - Avendaño-Solá, Cristina
AU  - Duarte Palomino, Rafael
AU  - Ramos-Martínez, Antonio
AU  - Ruiz-Antorán, Belén
PY  - 2021
DO  - 10.1186/s13063-020-05011-9
UR  - http://hdl.handle.net/20.500.12105/11789
AB  - COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes substantial morbidity and mortality. At the time this clinical trial was planned, there were no available vaccine or therapeutic agents with proven efficacy, but...
LA  - eng
PB  - BioMed Central (BMC)
KW  - Antibodies
KW  - COVID-19
KW  - Controlled trial
KW  - Convalescent plasma (CP)
KW  - Hospitalized patients
KW  - Neutralizing antibodies
KW  - Protocol
KW  - Randomized
KW  - Adult
KW  - COVID-19
KW  - Clinical Trials, Phase II as Topic
KW  - Female
KW  - Hospitalization
KW  - Humans
KW  - Immunization, Passive
KW  - Male
KW  - Middle Aged
KW  - Multicenter Studies as Topic
KW  - Randomized Controlled Trials as Topic
KW  - SARS-CoV-2
KW  - Severity of Illness Index
KW  - Standard of Care
KW  - Treatment Outcome
TI  - Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial.
TY  - research article
ER  -